Laboratory Corporation of America Holdings has recorded both gains and losses in its market performance recently. The company outperformed its competitors despite some losses and has even reached a 52-week high. There has been significant stock activity with entities like Lincoln National Corp and American National Bank increasing their holdings in LabCorp. However, LabCorp's EPS lags behind revenues, partially explaining inconsistencies in its market performance. It had a successful Q1 in 2024, beating earnings estimates and raising its EPS view for the year. Its financial activity is characterized by regular dividends of $0.72. LabCorp is also diversifying its operational scope by acquiring Baystate Health's outreach lab business and assets of Invitae and BioReference Health's diagnostics. LabCorp's strategic moves include its collaboration with Philips to advance in digital pathology and Hawthorne Effect to bring clinical trials directly to patients. Despite the mixed financial results, LabCorp continues to strengthen its diagnostics capabilities by introducing new tests, such as a preeclampsia risk assessment and a monkeypox test, securing FDA's EUA approval for its home Mpox testing kit.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Sat, 18 May 2024 22:30:17 GMT -
Rating 5
- Innovation 9
- Information 8
- Rumor 6
